Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunit Das

Showing results (21-30 of 236) with videos related to

Pageof 24
Sort By:
Chest|August 9, 2024
COUNTERPOINT: Is It Ethically Permissible to Use Frailty Scoring to Determine the Allocation of Medical Resources Under Conditions of Scarcity in the Medical ICU? NoChloë G K Atkins, Sunit Das
Journal of Neuro-Oncology|February 22, 2023
Correction: The role of immune checkpoint inhibitors in patients with intracranial metastatic diseaseZeel Patel, Matthew Cho, Sunit Das
Journal of Neuro-Oncology|February 14, 2014
Mouse models of glioblastoma: lessons learned and questions to be answeredLoury Janbazian, Jason Karamchandani, Sunit Das
Frontiers in Oncology|November 14, 2024
Radioresistance and brain metastases: a review of the literature and applied perspectiveAndrew Youssef, Arjun Sahgal, Sunit Das
JAMA Neurology|August 27, 2014
IDH mutation in glioma: new insights and promises for the futureZorbey Turkalp, Jason Karamchandani, Sunit Das
Frontiers in Oncology|October 17, 2017
The Role of ATRX in Glioma BiologyPravanya Nandakumar, Alireza Mansouri, Sunit Das
Expert Review of Neurotherapeutics|October 18, 2007
Chordomas of the craniospinal axis: multimodality surgical, radiation and medical management strategiesKenji Muro, Sunit Das, Jeffrey J Raizer
Operative Neurosurgery (Hagerstown, Md.)|November 29, 2017
Letter: Spontaneous Third Ventriculostomy in a Patient Following Traumatic Brain InjuryHissah Al Abdulsalam, Farshad Nissiri, Sunit Das
Current Treatment Options in Oncology|March 26, 2008
Immunotherapeutic treatment strategies for primary brain tumorsSunit Das, Jeffrey J Raizer, Kenji Muro
Frontiers in Oncology|February 22, 2020
Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialSunit Das, Arjun Sahgal, James R Perry
Pageof 24

Showing results (21-30 of 236) with videos related to

Sort By:
Pageof 24
Chest|August 9, 2024
COUNTERPOINT: Is It Ethically Permissible to Use Frailty Scoring to Determine the Allocation of Medical Resources Under Conditions of Scarcity in the Medical ICU? NoChloë G K Atkins, Sunit Das
Journal of Neuro-Oncology|February 22, 2023
Correction: The role of immune checkpoint inhibitors in patients with intracranial metastatic diseaseZeel Patel, Matthew Cho, Sunit Das
Journal of Neuro-Oncology|February 14, 2014
Mouse models of glioblastoma: lessons learned and questions to be answeredLoury Janbazian, Jason Karamchandani, Sunit Das
Frontiers in Oncology|November 14, 2024
Radioresistance and brain metastases: a review of the literature and applied perspectiveAndrew Youssef, Arjun Sahgal, Sunit Das
JAMA Neurology|August 27, 2014
IDH mutation in glioma: new insights and promises for the futureZorbey Turkalp, Jason Karamchandani, Sunit Das
Frontiers in Oncology|October 17, 2017
The Role of ATRX in Glioma BiologyPravanya Nandakumar, Alireza Mansouri, Sunit Das
Expert Review of Neurotherapeutics|October 18, 2007
Chordomas of the craniospinal axis: multimodality surgical, radiation and medical management strategiesKenji Muro, Sunit Das, Jeffrey J Raizer
Operative Neurosurgery (Hagerstown, Md.)|November 29, 2017
Letter: Spontaneous Third Ventriculostomy in a Patient Following Traumatic Brain InjuryHissah Al Abdulsalam, Farshad Nissiri, Sunit Das
Current Treatment Options in Oncology|March 26, 2008
Immunotherapeutic treatment strategies for primary brain tumorsSunit Das, Jeffrey J Raizer, Kenji Muro
Frontiers in Oncology|February 22, 2020
Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trialSunit Das, Arjun Sahgal, James R Perry
Pageof 24